20
Participants
Start Date
January 31, 2008
Primary Completion Date
March 31, 2010
Study Completion Date
June 30, 2010
LBH589
LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
Center for Cancer and Blood Disorders, Bethesda
Peninsula Cancer Institute, Newport News
Northeast Georgia Medical Center, Gainesville
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Oncology Hematology Care, Cincinnati
Methodist Cancer Center, Omaha
Baton Rouge General Medical Center, Baton Rouge
Hematology Oncology Associates of Northern NJ, Morristown
Collaborators (1)
Novartis
INDUSTRY
SCRI Development Innovations, LLC
OTHER